Clinical Trials Browser

Ovarian Neoplasms × sacituzumab govitecan × 90 days × Clear all

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Phase 2 Active not recruiting

Ovarian Neoplasms